New fixed-dose combination diabetes drug to undergo human clinical trials

ringi said:

I don't like most hybrid drugs, but in this case it makes sense as otherwise two injections would be needed after each meal.

Click to expand...

ickihun said:

This is referring to tablets. I'm led to believe. China has mixed metformin with other tablets to make hybrids.

Click to expand...

Lally123 said:

We do have combined tablets here too metformin and something else (cant remember what) But the OP on this thread must be referring to injections as you can't take insulin by mouth as insulin is a protein and would not survive digestion!

Click to expand...

ickihun said:

Sorry I've edited my message. I'm slow proof reading my posts this morning.
Your right.

I have edited.

Are you on dual diabetic tablet then?

Click to expand...

Diakat said:

Funnily enough an extra injection wouldn't bother me....

Click to expand...

DCUK NewsBot said:

The first human trials have begun of a fixed-dose combination drug of human insulin and pramlintide to help treat type 1 diabetes. The drug is called BioChaperone Pramlintide, developed by biotechnology company Adocia, which aims to improve blood glucose levels following meals. It combines Symlin (pramlintide), a synthetic version of the natural hormone amylin which can help improve postprandial blood sugars, and Adocia's BioChaperone technology, which helps to optimise the performance of drugs. While insulin regulates glucose levels, amylin helps to suppress glucagon, but as type 1 diabetes progresses neither hormone is eventually secreted. By combining human insulin and the synthetic pramlintide drug, researchers hope to mimic the way amylin and insulin are secreted from pancreatic beta cells. Researchers also hope to fully realise the potential of Symlin, the only FDA-approved amylin analog drug to be used alongside insulin, which is not approved in the UK by the NHS. While Symlin has helped improve HbA1c and induce weight loss in people with type 1 diabetes and type 2 diabetes when added to insulin therapy, patient adherence to both insulin and Symlin has shown to be poor. Adocia's BioChaperone technology will be directed to increase the effectiveness of pramlintide, making it easier to use for patients. "By removing the adherence barrier presented by additional injections, we hope to fully realize the therapeutic potential of pramlintide for people with type 1 diabetes," said Dr. Stan Glezer, Adocia’s Chief Medical Officer. In this new trial, 24 people with type 1 diabetes will be randomly assigned to BioChaperone Pramlintide in sequence with two other treatments, with safety, tolerance and blood glucose levels after meals among the primary objectives. The study is expected to be completed towards the end of 2018.

Continue reading...

Click to expand...

ringi said:

Most of the dual tablets that contain metformin (At least in the USA) cost no more then the version without metaformin.

Click to expand...